PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of "Moderate Buy" by Analysts

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $70.00.

PRCT has been the topic of several research analyst reports. Wall Street Zen raised PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Morgan Stanley dropped their price objective on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 15th. BTIG Research reissued a "neutral" rating on shares of PROCEPT BioRobotics in a research note on Tuesday, September 16th. Wells Fargo & Company dropped their price objective on PROCEPT BioRobotics from $75.00 to $58.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of PROCEPT BioRobotics in a research note on Saturday, September 27th.

PROCEPT BioRobotics Trading Up 3.4%

PRCT opened at $35.97 on Friday. PROCEPT BioRobotics has a one year low of $34.01 and a one year high of $103.81. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -23.21 and a beta of 0.99. The stock's 50 day moving average price is $40.51 and its 200-day moving average price is $51.32. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.86 and a current ratio of 9.21.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. PROCEPT BioRobotics had a negative return on equity of 23.73% and a negative net margin of 30.60%.The company had revenue of $79.18 million for the quarter, compared to analysts' expectations of $75.67 million. During the same quarter in the prior year, the firm earned ($0.50) earnings per share. PROCEPT BioRobotics's revenue was up 48.3% compared to the same quarter last year. On average, equities analysts forecast that PROCEPT BioRobotics will post -1.75 EPS for the current year.

Institutional Trading of PROCEPT BioRobotics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd bought a new stake in PROCEPT BioRobotics during the 1st quarter valued at $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in PROCEPT BioRobotics during the 1st quarter valued at $40,000. Vega Investment Solutions boosted its position in PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company's stock valued at $45,000 after acquiring an additional 265 shares in the last quarter. CWM LLC boosted its position in PROCEPT BioRobotics by 69.5% during the 1st quarter. CWM LLC now owns 873 shares of the company's stock valued at $51,000 after acquiring an additional 358 shares in the last quarter. Finally, AlphaQuest LLC boosted its position in PROCEPT BioRobotics by 1,262.5% during the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company's stock valued at $63,000 after acquiring an additional 1,010 shares in the last quarter. Institutional investors own 89.46% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.